Invisible burden, visible impact: Improving mental health outcomes in dermatology

Background: Chronic skin conditions are associated with a substantial psychosocial burden that remains underrecognised in clinical practice and society. Stigma has emerged as a key contributor to this burden. Both public stigma, reflected in societal attitudes and behaviours, and perceived stigma, referring to patients’ experiences of devaluation and social rejection, may contribute substantially to psychological morbidity.

Aims: This lecture synthesizes recent evidence on the experience and mental health burden of stigma in dermatology, drawing on large-scale adult and paediatric studies, and recent experimental work. 

Results: Recent evidence demonstrates that perceived stigmatization is elevated across a broad range of skin conditions and is associated with significant mental health burden. Furthermore, a multicenter study in pediatric skin conditions showed that the vast majority of children experience stigmatization, which was strongly related to impaired quality of life and childhood depression.
Notably, the weak association with disease visibility suggests that reliance on visible severity as a proxy for psychosocial burden is insufficient in clinical practice. Preliminary results from recent experimental work extend these findings by showing that avoidance behaviour towards people with chronic skin conditions is associated with germ aversion, disgust, and lower disease-related knowledge, suggesting that behavioral expressions of public stigma may be partially driven by modifiable factors such as knowledge.

Conclusions: Stigma is a clinically relevant aspect of disease burden in chronic skin conditions and is associated with impaired mental health outcomes across age groups and diagnoses. In clinical practice, these findings support systematic attention to stigmatization and its mental health burden from an early age, alongside timely referral to psychosocial support when needed. This approach may strengthen patient-centered management and facilitate early identification of patients at risk of psychological comorbidity.

At a broader level, emerging evidence on behavioral expressions of public stigma suggests that improving disease-related knowledge and reducing misconceptions about contagion may represent promising intervention strategies.

Key take home messages: Perceived and public stigma are distinct but interrelated dimensions of disease burden in chronic skin conditions, with clinically relevant psychosocial consequences from childhood onwards.  Psychosocial burden in dermatology is not adequately captured by disease severity or visibility alone, underscoring the need for systematic clinical attention to stigma.  Novel experimental evidence suggests that public stigma may manifest in observable behavioral responses, highlighting the importance of moving beyond self-report measures to better understand and address stigma.